Its arguably a drug rather than strictly a stem cell treatment, being a "stem cell regenerative pigment epithelium-derived factor-derived short peptide":
https://www.ophthalmologytimes.com/view/brim-biotechnology-receives-fda-orphan-drug-designation-for-treatment-of-neurotrophic-keratitis
But again, an ever improving backdrop for OCC and its ATI pathway with the FDA alongside all the recent autologous cellular therapy approvals, including stem cells.
(not that you'd know it from investor sentiment on this stock, yawn)
Stem Cell Therapy advancements, page-352
-
- There are more pages in this discussion • 129 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
64.5¢ |
Change
-0.040(5.84%) |
Mkt cap ! $135.8M | |||
| Open | High | Low | Value | Volume |
| 68.5¢ | 68.5¢ | 64.0¢ | $608.4K | 935.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11562 | 64.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.0¢ | 3800 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |